A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
This single arm study will assess the efficacy of loading doses of intravenous Bondronat in reducing pain in patients with breast cancer and metastatic bone disease experiencing moderate to severe bone pain. Patients will receive an intravenous infusion of 6mg Bondronat on days 1, 2 and 3. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.
Pain|Bone Neoplasm|Neoplasm Metastasis
DRUG: ibandronate [Bondronat]
Pain response (20% decrease in mean pain score compared to baseline, and <=50% increase in mean analgesic consumption, Days 5 - 7
Mean worst pain score over first 7 days, Day 7|Analgesic consumption, Day 7|Karnofsky index, Day 7|AEs, laboratory parameters, Throughout study
This single arm study will assess the efficacy of loading doses of intravenous Bondronat in reducing pain in patients with breast cancer and metastatic bone disease experiencing moderate to severe bone pain. Patients will receive an intravenous infusion of 6mg Bondronat on days 1, 2 and 3. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.